CHP
ATRA icon

Cable Hill Partners’s Atara Biotherapeutics ATRA Stock Holding History

Cable Hill Partners’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5
Closed -$5K – 149
2019
Q1 		$5K Hold
5
– – ﹤0.01% 593
2018
Q4 		$5K Hold
5
– – ﹤0.01% 551
2018
Q3 		$5K Sell
5
-1
-17% -$978 ﹤0.01% 553
2018
Q2 		$6K Hold
6
– – ﹤0.01% 590
2018
Q1 		$5K Sell
6
-10
-63% -$9.11K ﹤0.01% 643
2017
Q4 		$7K Hold
16
– – ﹤0.01% 643
2017
Q3 		$7K Sell
16
-1
-6% -$377 ﹤0.01% 660
2017
Q2 		$6K Hold
17
– – ﹤0.01% 505
2017
Q1 		$9K Sell
17
-1
-6% -$414 ﹤0.01% 407
2016
Q4 		$6K Buy
18
+9
+100% +$3.81K ﹤0.01% 501
2016
Q3 		$4K Sell
9
-1
-10% -$543 ﹤0.01% 602
2016
Q2 		$6K Hold
10
– – ﹤0.01% 461
2016
Q1 		$5K Buy
10
+1
+11% +$450 ﹤0.01% 469
2015
Q4 		$7K Buy
9
+4
+80% +$3.03K 0.01% 410
2015
Q3 		$4K Buy
+5
New +$6.1K ﹤0.01% 520

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Cable Hill Partners's ATRA Position: Q2 2019 in Review

Cable Hill Partners sold out of Atara Biotherapeutics (ATRA) in Q2 2019, closing a stake of 5 shares — an estimated $5K sold.

Cable Hill Partners first reported a position in ATRA in Q3 2015 and held it in 15 quarters. The position peaked at $9K in Q1 2017. 116 funds tracked by Wall St. Rank hold ATRA as of Q2 2019.

  • Cable Hill Partners reported no remaining Atara Biotherapeutics position as of Q2 2019 after selling out during the quarter.
  • Cable Hill Partners sold 5 Atara Biotherapeutics shares in Q2 2019, an estimated $5K.
  • Cable Hill Partners first reported a position in Atara Biotherapeutics in Q3 2015 and held it in 15 quarters.
  • Cable Hill Partners's Atara Biotherapeutics position peaked at $9K in Q1 2017.
  • 116 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2019.

Based on Cable Hill Partners's 13F filing for Q2 2019, filed 6 Aug 2019.